Login
$PSNL
$14.59 -$0.21 (1.42%) After hours

Company Executives

Officer Age Joined 2025 pay Source
Christopher Hall Also a director
Chief Executive Officer and Director
58 2022 $3,505,978
Aaron Tachibana
Chief Financial Officer and Chief Operating Officer
66 Not stated $1,608,300
Richard Chen, M.D., M.S.
President, Executive Vice President, Research and Development, and Chief Medical Officer
56 Not stated $1,589,150
Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
55 Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Average tenure
5.0 years
from year joined
Director Age On board Other public boards Pay Source
Christopher Hall
58 Not stated None stated Paid as CEO
Olivia K. Bloom
57 2022
4 years
None stated Not stated
A. Blaine Bowman
80 2019
7 years
None stated Not stated
Karin Eastham
76 2019
7 years
Veracyte, Inc. Not stated
Woodrow A. Myers, Jr., M.D.
72 2021
5 years
None stated Not stated
Lonnie Shoff
67 2022
4 years
None stated Not stated
Kenneth J. Widder, M.D.
73 2023
3 years
QuidelOrtho Corporation Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

10 disclosed in the proxy filed Apr 2, 2026
Tempus
Amount not stated

Commercialization and reference laboratory agreement under which Tempus markets NeXT Personal Dx in the United States

Tempus
$12.0 million

Development activity fees Tempus agreed to pay us under the Tempus Agreement

Tempus
Up to $9.6 million
through the end of 2026

Co-promotion arrangement under which we compensate Tempus for promotional and commercialization services

Tempus
Amount not stated
July 2025

Amendment extending the Tempus Agreement term and adding a fourth indication

Tempus
beneficial owner of approximately 15.8% of our common stock
Amount not stated
November 2023

Tempus Warrants to purchase 4,609,400 shares at $1.50 and 4,609,400 shares at $2.50 issued as partial consideration under the Tempus Agreement

Tempus
beneficial owner of approximately 15.8% of our common stock
$18.4 million
August 2024

Exercise in full of the Tempus Warrants for 9,218,800 shares

Tempus
beneficial owner of approximately 19.3% of our common stock immediately after closing
$17.7 million
August 2024

Sale of 3,500,000 shares of our common stock to Tempus under the Tempus Investment Agreement

Merck Sharp & Dohme LLC
became a related party in December 2024
$50.0 million
December 2024

Sale of 14,044,943 shares of our common stock to Merck under the Merck Investment Agreement

Merck Sharp & Dohme LLC
became a related party in December 2024
Amount not stated

Master Service Agreement under which Merck engaged us for DNA and RNA sequencing, data interpretation, compound synthesis and analysis services, amended in February 2024 to add clinical laboratory services

Merck Sharp & Dohme LLC
became a related party in December 2024
$2.0 million

Genomic testing services invoiced to Merck under the Master Agreement

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support